Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Enterprise Value (2016 - 2025)

Corcept Therapeutics' Enterprise Value history spans 10 years, with the latest figure at -$372.2 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 2.92% year-over-year to -$372.2 million; the TTM value through Dec 2025 reached -$372.2 million, up 2.92%, while the annual FY2025 figure was -$372.2 million, 2.92% up from the prior year.
  • Enterprise Value for Q4 2025 was -$372.2 million at Corcept Therapeutics, up from -$421.7 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$223.5 million in Q4 2021 and bottomed at -$473.2 million in Q2 2024.
  • The 5-year median for Enterprise Value is -$371.1 million (2022), against an average of -$376.5 million.
  • The largest annual shift saw Enterprise Value skyrocketed 49.28% in 2021 before it plummeted 93.11% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$223.5 million in 2021, then tumbled by 93.11% to -$431.7 million in 2022, then rose by 14.7% to -$368.2 million in 2023, then dropped by 4.1% to -$383.3 million in 2024, then rose by 2.92% to -$372.2 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Enterprise Value are -$372.2 million (Q4 2025), -$421.7 million (Q3 2025), and -$342.2 million (Q2 2025).